| Year |
Citation |
Score |
| 2018 |
Chappell WH, Candido S, Abrams SL, Russo S, Ove R, Martelli AM, Cocco L, Ramazzotti G, Cervello M, Montalto G, Steelman LS, Leng X, Arlinghaus RB, Libra M, McCubrey JA. Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation. PMID 29861174 DOI: 10.1016/J.Jbior.2018.05.002 |
0.323 |
|
| 2016 |
Chakraborty SN, Leng X, Perazzona B, Sun X, Lin YH, Arlinghaus RB. Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia. Genes & Cancer. 7: 201-8. PMID 27551334 DOI: 10.18632/Genesandcancer.111 |
0.379 |
|
| 2016 |
Mu C, Wu X, Ma H, Tao W, Zhang G, Xia X, Shen J, Mai J, Sun T, Sun X, Arlinghaus RB, Shen H. Effective concentration of a multi-kinase inhibitor within bone marrow correlates with in vitro cell killing in therapy-resistant chronic myeloid leukemia. Molecular Cancer Therapeutics. PMID 26846820 DOI: 10.1158/1535-7163.Mct-15-0577-T |
0.435 |
|
| 2016 |
Ochieng J, Nunomura S, Lang W, Wei J, Xu L, McDowell C, Ostrin E, Arlinghaus R, Fujimoto J, Kadara H. Abstract 1124: Expression of the lipocalin 2 oncogene in the development of smoking-associated and Kras mutant lung adenocarcinoma Cancer Research. 76: 1124-1124. DOI: 10.1158/1538-7445.Am2016-1124 |
0.308 |
|
| 2015 |
Tao W, Chakraborty SN, Leng X, Ma H, Arlinghaus RB. HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells. Genes & Cancer. 6: 19-29. PMID 25821558 DOI: 10.18632/Genesandcancer.49 |
0.427 |
|
| 2015 |
Mallampati S, Leng X, Ma H, Zeng J, Li J, Wang H, Lin K, Lu Y, Yang Y, Sun B, Gong Y, Lee JS, Konopleva M, Andreeff M, Arlinghaus RB, et al. Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. Blood. 125: 2968-73. PMID 25712988 DOI: 10.1182/Blood-2014-05-576421 |
0.42 |
|
| 2014 |
Ma H, Mallampati S, Lu Y, Sun B, Wang E, Leng X, Gong Y, Shen H, Yin CC, Jones D, Amin HM, You MJ, Zweidler-McKay P, Ma Y, Kantarjian HM, ... Arlinghaus RB, et al. The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. Haematologica. 99: 1591-8. PMID 24997151 DOI: 10.3324/Haematol.2014.104695 |
0.406 |
|
| 2014 |
Tao W, Leng X, Chakraborty SN, Ma H, Arlinghaus RB. c-Abl activates janus kinase 2 in normal hematopoietic cells. The Journal of Biological Chemistry. 289: 21463-72. PMID 24923444 DOI: 10.1074/Jbc.M114.554501 |
0.398 |
|
| 2013 |
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, ... ... Arlinghaus RB, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951 |
0.447 |
|
| 2013 |
Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, ... Arlinghaus RB, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34. PMID 23926298 DOI: 10.1182/Blood-2013-03-492181 |
0.457 |
|
| 2013 |
Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute. 105: 405-23. PMID 23446755 DOI: 10.1093/Jnci/Djt006 |
0.481 |
|
| 2012 |
Chappell WH, Abrams SL, Montalto G, Cervello M, Martelli AM, Candido S, Libra M, Polesel J, Talamini R, Arlinghaus R, Steelman LS, McCubrey JA. Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget. 3: 1236-45. PMID 23100449 DOI: 10.18632/Oncotarget.691 |
0.32 |
|
| 2012 |
Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty SN, Suzuki F, Arlinghaus RB, Liu J, Mobley JA, Grizzle WE, et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell. 21: 196-211. PMID 22340593 DOI: 10.1016/J.Ccr.2011.12.025 |
0.414 |
|
| 2012 |
Singh MM, Irwin ME, Gao Y, Ban K, Shi P, Arlinghaus RB, Amin HM, Chandra J. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer. 118: 3433-45. PMID 22139798 DOI: 10.1002/Cncr.26621 |
0.406 |
|
| 2012 |
Zhang H, Lu W, Liu T, Chen G, Chen Z, Trachootham D, Arlinghaus RB, Huang P. Abstract 2007: Differential roles of BCL-XL and BCL-2 in protecting mitochondria against oxidative stress in CML cells Cancer Research. 72: 2007-2007. DOI: 10.1158/1538-7445.Am2012-2007 |
0.354 |
|
| 2011 |
Corrado C, Raimondo S, Flugy AM, Fontana S, Santoro A, Stassi G, Marfia A, Iovino F, Arlinghaus R, Kohn EC, Leo GD, Alessandro R. Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. Cancer Letters. 300: 205-14. PMID 21041018 DOI: 10.1016/J.Canlet.2010.10.007 |
0.44 |
|
| 2011 |
Perazzona B, Lin Y, Arlinghaus RB. K562-R As a Model to Study Jak2 in a Non Bcr-Abl Addicted Cell Line Blood. 118: 4412-4412. DOI: 10.1182/Blood.V118.21.4412.4412 |
0.424 |
|
| 2011 |
Tao W, Leng X, Arlinghaus RB. The Role of c-Abl in Jak2 Activation in IL-3-Dependent Cells Blood. 118: 1672-1672. DOI: 10.1182/Blood.V118.21.1672.1672 |
0.461 |
|
| 2011 |
Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, ... ... Arlinghaus R, et al. Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-109 |
0.424 |
|
| 2010 |
Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, Priebe W, Arlinghaus R. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia. 25: 463-72. PMID 21183952 DOI: 10.1038/Leu.2010.287 |
0.477 |
|
| 2010 |
Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB. Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes & Cancer. 1: 346-59. PMID 20798787 DOI: 10.1177/1947601910372232 |
0.472 |
|
| 2010 |
Jatiani SS, Cosenza SC, Reddy MV, Ha JH, Baker SJ, Samanta AK, Olnes MJ, Pfannes L, Sloand EM, Arlinghaus RB, Reddy EP. A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes & Cancer. 1: 331-45. PMID 20717479 DOI: 10.1177/1947601910371337 |
0.462 |
|
| 2010 |
Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. Journal of Cellular and Molecular Medicine. 14: 1777-92. PMID 19508387 DOI: 10.1111/J.1582-4934.2009.00795.X |
0.395 |
|
| 2010 |
Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, ... ... Arlinghaus RB, et al. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment Blood. 116: 515-515. DOI: 10.1182/Blood.V116.21.515.515 |
0.411 |
|
| 2010 |
Chen M, Zhou L, Chan M, Lai D, Turhan AG, Arlinghaus RB, Jiang X. The WD40-Repeats of Ahi-1 Oncogene Critical for Protein Interaction Between Ahi-1 and BCR-ABL Modulates Imatinib-Induced Apoptosis In BCR-ABL-Transduced Cells Blood. 116: 4181-4181. DOI: 10.1182/Blood.V116.21.4181.4181 |
0.459 |
|
| 2010 |
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H, Saw KM, Chan M, Newmarch K, Zhou L, Turhan AG, Arlinghaus RB, Eaves AC, et al. Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. Blood. 116: 3404-3404. DOI: 10.1182/Blood.V116.21.3404.3404 |
0.445 |
|
| 2010 |
Samanta AK, Perazzona B, Chakraborty SN, Sun X, Modi H, Bhatia R, Arlinghaus RB. Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients. Blood. 116: 1220-1220. DOI: 10.1182/Blood.V116.21.1220.1220 |
0.406 |
|
| 2009 |
Leng X, Ding T, Lin H, Wang Y, Wu Y, Arlinghaus RB. WITHDRAWN: Requirement of lipocalin 2 in breast cancer. Advances in Enzyme Regulation. PMID 19914274 DOI: 10.1016/J.Advenzreg.2009.10.001 |
0.492 |
|
| 2009 |
Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Research. 69: 8579-84. PMID 19887608 DOI: 10.1158/0008-5472.Can-09-1934 |
0.545 |
|
| 2009 |
Leng X, Ding T, Arlinghaus R. Requirement of lipocalin 2 for hematopoietic and solid tumor malignancies. Advances in Enzyme Regulation. 49: 142-6. PMID 19344630 DOI: 10.1016/J.Advenzreg.2009.01.010 |
0.602 |
|
| 2009 |
Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR, Zhang W. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 531-48. PMID 19308044 DOI: 10.1038/Labinvest.2009.17 |
0.332 |
|
| 2009 |
Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients Oncogene. 28: 1669-1681. PMID 19234487 DOI: 10.1038/Onc.2009.7 |
0.47 |
|
| 2009 |
Muehlberg FL, Song YH, Krohn A, Pinilla SP, Droll LH, Leng X, Seidensticker M, Ricke J, Altman AM, Devarajan E, Liu W, Arlinghaus RB, Alt EU. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis. 30: 589-97. PMID 19181699 DOI: 10.1093/Carcin/Bgp036 |
0.326 |
|
| 2009 |
Samanta AK, Chakraborty SN, Sun X, Schlette E, Priebe W, Arlinghaus RB. Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia. Blood. 114: 39-39. DOI: 10.1182/Blood.V114.22.39.39 |
0.516 |
|
| 2009 |
Tao W, Samanta AK, Priebe W, Arlinghaus RB. Enhanced Jak2 Activation Correlates with β Chain Expression Leading to Phosphorylation of Tyrosine 177 of Bcr-Abl. Blood. 114: 2170-2170. DOI: 10.1182/Blood.V114.22.2170.2170 |
0.426 |
|
| 2008 |
Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, Sun T, Zhou Y, Monaco P, Belmont J, Aderem A, Akira S, Strong R, Arlinghaus R. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene. 27: 6110-9. PMID 18663364 DOI: 10.1038/Onc.2008.209 |
0.613 |
|
| 2008 |
Arlinghaus R, Leng X. Requirement of lipocalin 2 for chronic myeloid leukemia Leukemia and Lymphoma. 49: 600-603. PMID 18398717 DOI: 10.1080/10428190701859664 |
0.475 |
|
| 2008 |
Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene. 27: 4385-91. PMID 18391983 DOI: 10.1038/onc.2008.86 |
0.324 |
|
| 2008 |
Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism Leukemia. 22: 1191-1199. PMID 18385754 DOI: 10.1038/Leu.2008.74 |
0.399 |
|
| 2008 |
Ban K, Gao Y, Amin HM, Howard A, Miller C, Lin Q, Leng X, Munsell M, Bar-Eli M, Arlinghaus RB, Chandra J. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood. 111: 2904-8. PMID 18180382 DOI: 10.1182/Blood-2007-05-091769 |
0.472 |
|
| 2008 |
Ling D, Arlinghaus RB, Ling X. Vaccination with Leukemia Cell Expression Membrane Bound GM-CSF Overcomes the Host Immunosuppression Induced by Leukemia Blood. 112: 5435-5435. DOI: 10.1182/Blood.V112.11.5435.5435 |
0.342 |
|
| 2008 |
Mallampati S, Sun B, Gong Y, Wang E, You MJ, Amin HM, Ma Y, Shen H, Zweidler-McKay P, Jones D, Yin C, Glassman A, Kantarjian HM, Arlinghaus RB, Sun X. Rooting into the Soil, a Model for the Role of Sox4 in Leukemia Blood. 112: 3794-3794. DOI: 10.1182/Blood.V112.11.3794.3794 |
0.399 |
|
| 2008 |
Perazzona B, Wang Y, Arlinghaus RB. Role of BCR in Down-Modulation of BCR-ABL Oncogenicity in CML Blood. 112: 3210-3210. DOI: 10.1182/Blood.V112.11.3210.3210 |
0.493 |
|
| 2008 |
Samanta AK, Chakraborty SN, Samanta S, Wang Y, Sun X, Schlette E, Priebe W, Arlinghaus RB. Disruption of the Bcr-Abl/Jak2/HSP90 Network Complex Leading to Induction of Apoptosis in Drug-Resistant CML Cells by a New Compound WP1193 Blood. 112: 3199-3199. DOI: 10.1182/BLOOD.V112.11.3199.3199 |
0.32 |
|
| 2007 |
Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene. 27: 3194-200. PMID 18071309 DOI: 10.1038/Sj.Onc.1210979 |
0.392 |
|
| 2007 |
Perazzona B, Lin H, Sun T, Wang Y, Arlinghaus R. Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects. Oncogene. 27: 2208-14. PMID 17934518 DOI: 10.1038/Sj.Onc.1210851 |
0.491 |
|
| 2007 |
Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene. 26: 6989-96. PMID 17486070 DOI: 10.1038/Sj.Onc.1210500 |
0.435 |
|
| 2007 |
Saldanha J, Silvy M, Beaufils N, Arlinghaus R, Barbany G, Branford S, Cayuela JM, Cazzaniga G, Gonzalez M, Grimwade D, Kairisto V, Miyamura K, Lawler M, Lion T, Macintyre E, et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia. 21: 1481-7. PMID 17476280 DOI: 10.1038/Sj.Leu.2404716 |
0.337 |
|
| 2007 |
Tao W, Lin H, Sun T, Samanta AK, Arlinghaus RB. Oncogenic Transformation of NIH 3T3 Fibroblasts by BCR-ABL Oncoprotein Requires the IL-3 Receptor. Blood. 110: 3370-3370. DOI: 10.1182/Blood.V110.11.3370.3370 |
0.434 |
|
| 2007 |
Samanta AK, Chakravorty S, Wang Y, Cortes J, Kantarjian H, Champlin RE, Perrotti D, Arlinghaus RB. Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells. Blood. 110: 3342-3342. DOI: 10.1182/Blood.V110.11.3342.3342 |
0.497 |
|
| 2006 |
Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 10: 241-52. PMID 16959615 DOI: 10.1016/J.Ccr.2006.08.009 |
0.361 |
|
| 2006 |
Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Research. 66: 6468-72. PMID 16818614 DOI: 10.1158/0008-5472.Can-06-0025 |
0.479 |
|
| 2006 |
Ling X, Wang Y, Dietrich MF, Andreeff M, Arlinghaus RB. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice Oncogene. 25: 4483-4490. PMID 16547503 DOI: 10.1038/Sj.Onc.1209477 |
0.35 |
|
| 2006 |
Tao W, Sun T, Craig AR, Cortes JE, Ottmann OG, Hochhaus A, Reddy PE, Kantarjian HM, Arlinghaus RB. The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients. Blood. 108: 2179-2179. DOI: 10.1182/Blood.V108.11.2179.2179 |
0.388 |
|
| 2006 |
Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML). Blood. 108: 2121-2121. DOI: 10.1182/blood.v108.11.2121.2121 |
0.402 |
|
| 2006 |
ABE J, CHE W, YOSHIZUMI M, HUANG Q, GLASSMAN M, OHTA S, WU Y, ARLINGHAUS R, BERK BC. Bcr in Vascular Smooth Muscle Cells Annals of the New York Academy of Sciences. 947: 341-343. DOI: 10.1111/J.1749-6632.2001.Tb03959.X |
0.396 |
|
| 2005 |
Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4941-7. PMID 16000593 DOI: 10.1158/1078-0432.Ccr-04-2601 |
0.398 |
|
| 2005 |
Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Research. 65: 2532-6. PMID 15805244 DOI: 10.1158/0008-5472.CAN-04-2425 |
0.312 |
|
| 2005 |
Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene. 24: 3246-56. PMID 15735695 DOI: 10.1038/Sj.Onc.1208500 |
0.772 |
|
| 2005 |
Lin H, Leng X, Sun T, Monaco G, Stephens C, Belmont J, Arlinghaus R. Bcr-Abl-Mediated Suppression of Normal Hematopoiesis in Chronic Myeloid Leukemia: Involvement of a Modified Form of NGAL. Blood. 106: 2869-2869. DOI: 10.1182/Blood.V106.11.2869.2869 |
0.47 |
|
| 2004 |
Arlinghaus R, Sun T. Signal transduction pathways in Bcr-Abl transformed cells Cancer Treatment and Research. 119: 239-270. PMID 15164881 DOI: 10.1007/1-4020-7847-1_12 |
0.475 |
|
| 2004 |
Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M, Shishodin S. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Research. 64: 672-7. PMID 14744784 DOI: 10.1158/0008-5472.Can-03-1484 |
0.46 |
|
| 2004 |
Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nature Genetics. 36: 55-62. PMID 14702041 DOI: 10.1038/Ng1279 |
0.449 |
|
| 2004 |
Golemovic M, Beran M, Giles F, Manshouri T, Thomas D, Cortes J, Manley P, Alland L, Rae P, Dugan M, Estrov Z, Arlinghaus RB, Kantarjian H, Verstovsek S. AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells. Blood. 104: 2737-2737. DOI: 10.1182/Blood.V104.11.2737.2737 |
0.437 |
|
| 2003 |
Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T, Arlinghaus RB, Whitehead IP. The c-Myc Oncoprotein Interacts with Bcr. Current Biology : Cb. 13: 437-41. PMID 12620195 DOI: 10.1016/S0960-9822(03)00090-3 |
0.37 |
|
| 2003 |
Ling X, Ma G, Sun T, Liu J, Arlinghaus RB. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. Cancer Research. 63: 298-303. PMID 12543778 |
0.376 |
|
| 2003 |
Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 101: 690-8. PMID 12509383 DOI: 10.1182/Blood.V101.2.690 |
0.437 |
|
| 2002 |
Arlinghaus RB. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia. Oncogene. 21: 8560-7. PMID 12476302 DOI: 10.1038/Sj.Onc.1206083 |
0.434 |
|
| 2002 |
Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M, Glassman A, Arlinghaus RB. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients Leukemia. 16: 2447-2453. PMID 12454751 DOI: 10.1038/Sj.Leu.2402730 |
0.303 |
|
| 2002 |
Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 21: 7137-46. PMID 12370803 DOI: 10.1038/Sj.Onc.1205942 |
0.776 |
|
| 2002 |
Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer. 94: 2996-9. PMID 12115389 DOI: 10.1002/Cncr.10576 |
0.372 |
|
| 2002 |
Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Molecular Cell. 9: 993-1004. PMID 12049736 DOI: 10.1016/S1097-2765(02)00510-5 |
0.343 |
|
| 2002 |
Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, ... ... Arlinghaus RB, et al. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 94: 2416-25. PMID 12015767 DOI: 10.1002/Cncr.10490 |
0.327 |
|
| 2002 |
Lin H, Guo JQ, Andreeff M, Arlinghaus RB. Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient [1] Leukemia. 16: 294-297. PMID 11840298 DOI: 10.1038/Sj.Leu.2402353 |
0.328 |
|
| 2002 |
Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Research. 62: 386-90. PMID 11809685 |
0.745 |
|
| 2001 |
Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 20: 6188-95. PMID 11593427 DOI: 10.1038/Sj.Onc.1204834 |
0.773 |
|
| 2001 |
Che W, Abe J, Yoshizumi M, Huang Q, Glassman M, Ohta S, Melaragno MG, Poppa V, Yan C, Lerner-Marmarosh N, Zhang C, Wu Y, Arlinghaus R, Berk BC. p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells. Circulation. 104: 1399-406. PMID 11560856 DOI: 10.1161/Hc3701.095581 |
0.424 |
|
| 2001 |
Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood. 98: 1773-81. PMID 11535511 DOI: 10.1182/blood.V98.6.1773 |
0.375 |
|
| 2001 |
Lin F, Monaco G, Sun T, Liu J, Lin H, Stephens C, Belmont J, Arlinghaus RB. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model Oncogene. 20: 1873-1881. PMID 11313935 DOI: 10.1038/Sj.Onc.1204409 |
0.387 |
|
| 2001 |
Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M. Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification. British Journal of Haematology. 112: 749-59. PMID 11260080 DOI: 10.1111/J.1365-2141.2001.02510.X |
0.374 |
|
| 2001 |
Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death Cancer Research. 61: 138-144. PMID 11196151 |
0.325 |
|
| 2000 |
Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients Faseb Journal. 14: 1529-1538. PMID 10928987 |
0.38 |
|
| 2000 |
Xie S, Liu J, Sun T, Arlinghaus RB. Evidence that BCR-ABL activates JAK2 by direct tyrosine phosphorylation, and JAK2 activation by BCR-ABL is involved in blocking apoptosis Blood. 96. |
0.393 |
|
| 1999 |
Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J, Arlinghaus RB. Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene. 18: 4416-24. PMID 10442632 DOI: 10.1038/Sj.Onc.1202828 |
0.508 |
|
| 1999 |
Le XF, Groner Y, Kornblau SM, Gu Y, Hittelman WN, Levanon D, Mehta K, Arlinghaus RB, Chang KS. Regulation of AML2/CBFA3 in hematopoietic cells through the retinoic acid receptor α-dependent signaling pathway Journal of Biological Chemistry. 274: 21651-21658. PMID 10419474 DOI: 10.1074/Jbc.274.31.21651 |
0.342 |
|
| 1999 |
Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B, Cong F, Goff SP, Wu Y, Arlinghaus R, Baltimore D, Gasser PJ, Park MS, Sung P, Lee EY. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. The Journal of Biological Chemistry. 274: 12748-52. PMID 10212258 DOI: 10.1074/Jbc.274.18.12748 |
0.391 |
|
| 1999 |
Guo XD, Balague C, Wang T, Randhawa G, Yuan Z, Bachier C, Greenberger J, Arlinghaus R, Kufe D, Deisseroth AB. The presence of the Rb c-box peptide in the cytoplasm inhibits p210bcr-abl transforming function. Oncogene. 18: 1589-1595. PMID 10102629 DOI: 10.1038/Sj.Onc.1202479 |
0.423 |
|
| 1998 |
Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier C, Greenberger J, Colombowala I, Deisseroth AB. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene. 17: 825-33. PMID 9779999 DOI: 10.1038/Sj.Onc.1201999 |
0.393 |
|
| 1998 |
Arlinghaus RB. The involvement of Bcr in leukemias with the Philadelphia chromosome Critical Reviews in Oncogenesis. 9: 1-18. PMID 9754444 DOI: 10.1615/Critrevoncog.V9.I1.10 |
0.36 |
|
| 1998 |
Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing M(r) 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148) Clinical Cancer Research. 4: 1661-1672. PMID 9676840 |
0.413 |
|
| 1998 |
Yang Y, Pham CD, Vuyyuru VB, Liu H, Arlinghaus RB, Singh B. Evidence of a functional interaction between serine 3 and serine 25 Mos phosphorylation sites: A dominant inhibitory role of serine 25 phosphorylation on mos protein kinase Journal of Biological Chemistry. 273: 15946-15953. PMID 9632642 DOI: 10.1074/Jbc.273.26.15946 |
0.407 |
|
| 1998 |
Schenk TM, Keyhani A, Bottcher S, Kliche KO, Goodacre A, Guo JQ, Arlinghaus RB, Kantarjian HM, Andreeff M. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 12: 666-74. PMID 9593263 DOI: 10.1038/Sj.Leu.2400986 |
0.329 |
|
| 1998 |
Yang Y, Pham CD, Arlinghaus RB, Khillan JS, Singh B. Elevated level of cyclin D1 in mos-transformed cells International Journal of Oncology. 12: 1199-1202. PMID 9538150 DOI: 10.3892/Ijo.12.5.1199 |
0.418 |
|
| 1998 |
Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, Talpaz M, Arlinghaus RB. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon Leukemia. 12: 155-163. PMID 9519777 DOI: 10.1038/Sj.Leu.2400919 |
0.391 |
|
| 1998 |
Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase Oncogene. 16: 141-146. PMID 9467953 DOI: 10.1038/Sj.Onc.1201524 |
0.427 |
|
| 1997 |
Singh B, Arlinghaus RB. Mos and the cell cycle Progress in Cell Cycle Research. 3: 251-259. PMID 9552420 DOI: 10.1007/978-1-4615-5371-7_20 |
0.439 |
|
| 1997 |
Tari AM, Arlinghaus R, Lopez-Berestein G. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochemical and Biophysical Research Communications. 235: 383-8. PMID 9199202 DOI: 10.1006/Bbrc.1997.6791 |
0.428 |
|
| 1997 |
Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2 Oncogene. 14: 2367-2372. PMID 9178913 DOI: 10.1038/Sj.Onc.1201053 |
0.435 |
|
| 1997 |
Seong D, Giralt S, Fischer H, Hayes K, Glassman A, Arlinghaus R, Xu J, Kantarjian H, Siciliano M, Champlin R. Usefulness of detection of minimal residual disease by ‘hypermetaphase’ fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia Bone Marrow Transplantation. 19: 565-570. PMID 9085736 DOI: 10.1038/Sj.Bmt.1700700 |
0.335 |
|
| 1997 |
Tsui LV, Ramagli LS, Gao C, Pham CD, Pandita TK, Arlinghaus RB, Singh B. The biological effects of antisense mos expression in fibroblasts International Journal of Oncology. 11: 1171-1178. DOI: 10.3892/Ijo.11.6.1171 |
0.415 |
|
| 1997 |
Pham CD, Rungta M, Chandler DS, Yang Y, Arlinghaus RB, Rajagopalan S, Schwartz MR, Singh B. Essential role of c-mos in eggs: Reduced fertility and ovarian neoplasm in antisense mos transgenic mice International Journal of Gynecological Cancer. 7: 314-317. DOI: 10.1046/J.1525-1438.1997.00461.X |
0.32 |
|
| 1996 |
Liu J, Wu Y, Arlinghaus RB. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein Cancer Research. 56: 5120-5124. PMID 8912843 |
0.376 |
|
| 1996 |
Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients American Journal of Clinical Pathology. 106: 442-448. PMID 8853030 DOI: 10.1093/Ajcp/106.4.442 |
0.361 |
|
| 1996 |
Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Research. 56: 3426-30. PMID 8758906 |
0.746 |
|
| 1996 |
Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB. Inhibition of Bcr serine kinase by tyrosine phosphorylation Molecular and Cellular Biology. 16: 998-1005. PMID 8622703 DOI: 10.1128/Mcb.16.3.998 |
0.452 |
|
| 1996 |
Yang Y, Herrmann CH, Arlinghaus RB, Singh B. Inhibition of v-Mos kinase activity by protein kinase A Molecular and Cellular Biology. 16: 800-809. PMID 8622681 DOI: 10.1128/Mcb.16.3.800 |
0.421 |
|
| 1995 |
Pham CD, Arlinghaus RB, Zheng CF, Guan KL, Singh B. Characterization of MEK1 phosphorylation by the v-Mos protein Oncogene. 10: 1683-1688. PMID 7731726 |
0.324 |
|
| 1994 |
Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JYJ, Arlinghaus RB. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy Blood. 83: 3629-3637. PMID 8204887 DOI: 10.1182/Blood.V83.12.3629.3629 |
0.387 |
|
| 1994 |
Jagannadha Sastry K, Bender BS, Bell W, Small PA, Arlinghaus RB. Effects of influenza virus-specific cytotoxic T-lymphocyte responses induced by a synthetic nucleoprotein peptide on the survival of mice challenged with a lethal dose of virus Vaccine. 12: 1281-1287. PMID 7856292 DOI: 10.1016/S0264-410X(94)80053-3 |
0.305 |
|
| 1994 |
Ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia Blood. 84: 1731-1736. PMID 7521685 DOI: 10.1182/Blood.V84.6.1731.Bloodjournal8461731 |
0.456 |
|
| 1993 |
Tsui LV, Ramagli LS, Singh B, Nash M, Arlinghaus RB. Somatic-Cell Expression Of The Mos Protooncogene Is Cell-Cycle Regulated - Highest Rna Expression In The G2 Phase International Journal of Oncology. 2: 493-502. PMID 21573582 DOI: 10.3892/Ijo.2.4.493 |
0.359 |
|
| 1993 |
Nehete PN, Satterfield WC, Matherne CM, Arlinghaus RB, Sastry KJ. Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160 Aids Research and Human Retroviruses. 9: 235-240. PMID 8471313 DOI: 10.1089/Aid.1993.9.235 |
0.318 |
|
| 1993 |
Liu J, Campbell M, Guo JQ, Lu D, Xian YM, Andersson BS, Arlinghaus RB. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates p160 BCR on tyrosine predominantly within the first BCR exon Oncogene. 8: 101-109. PMID 8423987 |
0.304 |
|
| 1993 |
Campbell ML, Lu D, Guo JQ, Arlinghaus RB. Inhibition of phosphorylation of p160 BCR within p210 BCR-ABL complexes during early stages of phorbol ester-induced differentiation of K562 cells Cell Growth &Amp; Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 4: 581-588. PMID 8398898 |
0.356 |
|
| 1993 |
Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Szczylik C, Zon G, Arlinghaus RB, Gewirtz A, Perussia B, Calabretta B. p120 GAP requirement in normal and malignant human hematopoiesis Journal of Experimental Medicine. 178: 1923-1933. PMID 8245773 DOI: 10.1084/Jem.178.6.1923 |
0.336 |
|
| 1993 |
Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, Canaani E, Arlinghaus R. Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL Blood. 82: 1257-1263. DOI: 10.1182/Blood.V82.4.1257.Bloodjournal8241257 |
0.426 |
|
| 1992 |
Sastry KJ, Nehete PN, Venkatnarayanan S, Morkowski J, Platsoucas CD, Arlinghaus RB. Rapid in vivo induction of HIV-specific cd8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120 Virology. 188: 502-509. PMID 1316670 DOI: 10.1016/0042-6822(92)90504-I |
0.303 |
|
| 1992 |
Singh B, Stocking C, Walker R, Yang YD, Ostertag W, Arlinghaus RB. v-mos proteins encoded by myeloproliferative sarcoma virus and its ts159 mutant. Journal of Virology. 66: 1267-72. PMID 1309903 DOI: 10.1128/Jvi.66.2.1267-1272.1992 |
0.357 |
|
| 1991 |
Campbell ML, Arlinghaus RB. Current status of the BCR gene and its involvement with human leukemia Advances in Cancer Research. 57: 227-256. PMID 1950704 DOI: 10.1016/S0065-230X(08)61000-3 |
0.374 |
|
| 1991 |
Bai W, Singh B, Karshin WL, Shonk RA, Arlinghaus RB. Phosphorylation of v-mos Ser 47 by the mitotic form of p34cdc2 Oncogene. 6: 1715-1723. PMID 1833715 |
0.327 |
|
| 1991 |
Sastry KJ, Arlinghaus RB. Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein Aids. 5: 699-707. PMID 1715718 DOI: 10.1097/00002030-199106000-00009 |
0.356 |
|
| 1991 |
Weber M, Kubiak JZ, Arlinghaus RB, Pines J, Maro B. c-mos proto-oncogene product is partly degraded after release from meiotic arrest and persists during interphase in mouse zygotes Developmental Biology. 148: 393-397. PMID 1657664 DOI: 10.1016/0012-1606(91)90347-6 |
0.326 |
|
| 1990 |
Singh B, Al-Bagdadi F, Liu J, Arlinghaus RB. Use of antipeptide antibodies to probe the catalytic activity of p37v-mos Virology. 178: 535-542. PMID 2171192 DOI: 10.1016/0042-6822(90)90351-Q |
0.318 |
|
| 1990 |
Al-Bagdadi F, Singh B, Arlinghaus RB. Evidence for involvement of the protein kinase C pathway in the activation of p37v-mos protein kinase Oncogene. 5: 1251-1257. PMID 2168030 |
0.327 |
|
| 1990 |
Herzog NK, Nash M, Ramagli LS, Arlinghaus RB. v-mos protein produced by in vitro translation has protein kinase activity Journal of Virology. 64: 3093-3096. PMID 2159564 DOI: 10.1128/Jvi.64.6.3093-3096.1990 |
0.404 |
|
| 1990 |
Hamelin R, Honore N, Sergiescu D, Singh B, Gerfaux J, Arlinghaus RB. Reversion of thermosensitive splicing defect of moloney murine sarcoma virus ts110 by oversplicing of viral RNA Journal of Virology. 64: 1378-1382. PMID 2154617 DOI: 10.1128/Jvi.64.3.1378-1382.1990 |
0.352 |
|
| 1990 |
Roy LM, Singh B, Gautier J, Arlinghaus RB, Nordeen SK, Maller JL. The cyclin B2 component of MPF is a substrate for the c-mosxe proto-oncogene product Cell. 61: 825-831. PMID 2140529 DOI: 10.1016/0092-8674(90)90192-H |
0.404 |
|
| 1990 |
Liu J, Singh B, Wlodek D, Arlinghaus RB. Cell cycle-mediated structural and functional alteration of P85gag-mos protein kinase activity Oncogene. 5: 171-178. PMID 2138725 |
0.358 |
|
| 1989 |
Li W, Smith LA, Kabat KG, Kloetzer WS, Arlinghaus RB. Differential effects of tumor promoters on P210(bcr-abl) expression Hematologic Pathology. 3: 113-123. PMID 2687223 |
0.346 |
|
| 1989 |
Li W, Dreazen O, Kloetzer W, Gale RP, Arlinghaus RB. Characterization of bcr gene products in hematopoietic cells Oncogene. 4: 127-138. PMID 2648252 |
0.302 |
|
| 1989 |
Singh B, Arlinghaus RB. Vimentin phosphorylation by p37mos protein kinase in vitro and generation of a 50-kDa cleavage product in v-mos-transformed cells Virology. 173: 144-156. PMID 2554568 DOI: 10.1016/0042-6822(89)90230-4 |
0.449 |
|
| 1988 |
Singh B, Wittenberg C, Hannink M, Reed SI, Donoghue DJ, Arlinghaus RB. The histidine-221 to tyrosine substitution in v-mos abolishes its biological function and its protein kinase activity. Virology. 164: 114-20. PMID 2966489 DOI: 10.1016/0042-6822(88)90626-5 |
0.324 |
|
| 1987 |
Kurzrock R, Kloetzer WS, Talpaz M, Blick M, Walters R, Arlinghaus RB, Gutterman JU. Identification of molecular variants of p210(bcr-abl) in chronic myelogenous leukemia Blood. 70: 233-236. PMID 2885048 |
0.301 |
|
| 1987 |
Singh B, Goldman R, Hutton L, Herzog NK, Arlinghaus RB. The P55 protein affected by v-mos expression is vimentin Journal of Virology. 61: 3625-3629. PMID 2822968 DOI: 10.1128/Jvi.61.11.3625-3629.1987 |
0.377 |
|
| 1986 |
Steck PA, Gallick GE, Maxwell SA, Moser RP, Gutterman JU, Yung WKA, Kloetzer WS, Arlinghaus RB. Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells Journal of Cellular Biochemistry. 32: 1-10. PMID 3533968 DOI: 10.1002/jcb.240320102 |
0.302 |
|
| 1986 |
Singh B, Hannink M, Donoghue DJ, Arlinghaus RB. p37(mos)-Associated serine/threonine protein kinase activity correlates with the cellular transformation function of v-mos Journal of Virology. 60: 1148-1152. PMID 3023666 DOI: 10.1128/Jvi.60.3.1148-1152.1986 |
0.332 |
|
| 1986 |
Singh B, Wittenberg C, Reed SI, Arlinghaus RB. Moloney murine sarcoma virus encoded p37mos expressed in yeast has protein kinase activity. Virology. 152: 502-6. PMID 3014729 DOI: 10.1016/0042-6822(86)90156-X |
0.31 |
|
| 1985 |
Maxwell SA, Arlinghaus RB. Serine kinase activity associated with moloney murine sarcoma virus-124-encoded p37mos Virology. 143: 321-333. PMID 2998008 DOI: 10.1016/0042-6822(85)90119-9 |
0.344 |
|
| 1985 |
Gallick GE, Sparrow JT, Singh B, Maxwell SA, Stanker LH, Arlinghaus RB. Recognition of mos-related proteins with an antiserum to a peptide of the v-mos gene product. The Journal of General Virology. 66: 945-55. PMID 2987403 DOI: 10.1099/0022-1317-66-5-945 |
0.363 |
|
| 1985 |
Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology. 140: 230-8. PMID 2982232 DOI: 10.1016/0042-6822(85)90361-7 |
0.327 |
|
| 1985 |
Hamelin R, Brizzard BL, Nash MA, Murphy EC, Arlinghaus RB. Temperature-sensitive viral RNA expression in Moloney murine sarcoma virus ts110-infected cells. Journal of Virology. 53: 616-23. PMID 2982039 DOI: 10.1128/Jvi.53.2.616-623.1985 |
0.317 |
|
| 1984 |
Kloetzer WS, Maxwell SA, Arlinghaus RB. Further characterization of the P85gag-mos-associated protein kinase activity Virology. 138: 143-155. PMID 6093355 DOI: 10.1016/0042-6822(84)90154-5 |
0.358 |
|
| 1983 |
Naso RB, Stanker LH, Kopchick JJ, Ng VL, Karshin WL, Arlinghaus RB. Further studies on the glycosylated gag gene products of Rauscher murine leukemia virus: Identification of an N-terminal 45,000-dalton cleavage product Journal of Virology. 45: 1200-1206. PMID 6601196 DOI: 10.1128/Jvi.45.3.1200-1206.1983 |
0.356 |
|
| 1983 |
Stanker LH, Gallick GE, Horn JP, Arlinghaus RB. P85gag-mos encoded by ts110 Moloney murine sarcoma virus: rapid at the restrictive temperature. The Journal of General Virology. 64: 2203-11. PMID 6311952 DOI: 10.1099/0022-1317-64-10-2203 |
0.347 |
|
| 1983 |
Connor CG, Moore PB, Brady RC, Horn JP, Arlinghaus RB, Dedman JR. The role of calmodulin in cell transformation. Biochemical and Biophysical Research Communications. 112: 647-54. PMID 6303327 DOI: 10.1016/0006-291X(83)91512-7 |
0.315 |
|
| 1983 |
Stanker LH, Horn JP, Gallick GE, Kloetzer WS, Murphy EC, Blair DG, Arlinghaus RB. Gag-mos Polyproteins encoded by variants of the Moloney strain of mouse sarcoma virus. Virology. 126: 336-47. PMID 6302990 DOI: 10.1016/0042-6822(83)90483-X |
0.315 |
|
| 1983 |
Stanker LH, Gallick GE, Kloetzer WS, Murphy EC, Arlinghaus RB. P85: A gag-mos polyprotein encoded by ts110 Moloney murine sarcoma virus Journal of Virology. 45: 1183-1189. PMID 6300456 DOI: 10.1128/Jvi.45.3.1183-1189.1983 |
0.371 |
|
| 1983 |
Naso RB, Stanker LH, Kopchick JJ, Ng VL, Karshin WL, Arlinghaus RB. Further studies on the glycosylated gag gene products of Rauscher murine leukemia virus: identification of an N-terminal 45,000-dalton cleavage product. Journal of Virology. 45: 1200-1206. DOI: 10.1128/jvi.45.3.1200-1206.1983 |
0.382 |
|
| 1981 |
Kopchick JJ, Harless J, Geisser BS, Killam R, Hewitt RR, Arlinghaus RB. Endodeoxyribonuclease activity associated with Rauscher murine leukemia virus Journal of Virology. 37: 274-283. PMID 6260982 DOI: 10.1128/Jvi.37.1.274-283.1981 |
0.431 |
|
| 1980 |
Ng VL, Kopchick JJ, Karshin WL, Wood TG, Arlinghaus RB. The structural relatedness of the virus core proteins on Rauscher and Moloney murine leukaemia virus Journal of General Virology. 47: 161-170. PMID 7365462 DOI: 10.1099/0022-1317-47-1-161 |
0.502 |
|
| 1979 |
Kopchick JJ, Karshin WL, Arlinghaus RB. Tryptic peptide analysis of gag and gag-pol gene products of Rauscher murine leukemia virus Journal of Virology. 30: 610-623. PMID 469995 |
0.427 |
|
| 1979 |
Naso RB, Karshin WL, Wu YH, Arlinghaus RB. Characterization of 40,000- and 25,000-Dalton intermediate precursors to Rauscher murine leukemia virus gag gene products Journal of Virology. 32: 187-198. PMID 94357 DOI: 10.1128/Jvi.32.1.187-198.1979 |
0.397 |
|
| 1979 |
Ng VL, Wood TG, Lyons DD, Arlinghaus RB. Characterization of intracellular precursor polyproteins of Moloney murine leukemia virus Journal of Virology. 32: 1051-1056. PMID 92574 DOI: 10.1128/Jvi.32.3.1051-1056.1979 |
0.357 |
|
| 1978 |
Kopchick JJ, Jamjoom GA, Watson KF, Arlinghaus RB. Biosynthesis of reverse transcriptase from Rauscher murine leukemia virus by synthesis and cleavage of a gag-pol read-through viral precursor polyprotein Proceedings of the National Academy of Sciences of the United States of America. 75: 2016-2020. PMID 77022 |
0.455 |
|
| 1978 |
Murphy EC, Kopchick JJ, Watson KF, Arlinghaus RB. Cell-free synthesis of a precursor polyprotein containing both gag and pol gene products by Rauscher murine leukemia virus 35S RNA Cell. 13: 359-369. PMID 75071 DOI: 10.1016/0092-8674(78)90204-0 |
0.46 |
|
| 1977 |
Karshin WL, Arcement LJ, Naso RB, Arlinghaus RB. Common precursor for Rauscher leukemia virus gp69/71, p15(E), and p12(E) Journal of Virology. 23: 787-798. PMID 894795 DOI: 10.1128/Jvi.23.3.787-798.1977 |
0.314 |
|
| 1977 |
Gerry Robey W, Oskarsson MK, Vande Woude GF, Naso RB, Arlinghaus RB, Haapala DK, Fischinger PJ. Cells transformed by certain strains of moloney sarcoma virus contain murine p60 Cell. 10: 79-89. PMID 65230 DOI: 10.1016/0092-8674(77)90142-8 |
0.353 |
|
| 1961 |
Ogle JD, Arlinghaus RB, Logan MA. Studies on peptides obtained from enzymic digests of collagen with evidence for the presence of an unidentified compound in this protein Archives of Biochemistry and Biophysics. 94: 85-93. PMID 13730445 DOI: 10.1016/0003-9861(61)90014-5 |
0.595 |
|
| Show low-probability matches. |